Serial [18F]Fluorodeoxyglucose Positron Emission Tomography after Human Neuronal Implantation for Stroke

Meltzer, Carolyn C.; Kondziolka, Douglas; Villemagne, Victor L.; Wechsler, Lawrence R.; Goldstein, Steven; Thulborn, Keith R.; Gebel, James; Elder, Elaine M.; DeCesare, Sharon; Jacobs, Alan J.

doi:10.1227/00006123-200109000-00011

Cited by 40 publications

(45 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…66,2009 Review Article 765 absence of a continuous immunosuppressant regimen [146]. PET, performed at 6 months, showed high uptake of F-18 fluorodeoxyglucose at the site of transplantation in six patients, suggesting either graft survival or inflammatory response [147]. Although this trial was not designed to evaluate efficacy, 6 patients presented improvement according to the European Stroke Scale (ESS) scores at 24 weeks and in some patients it correlated with increased PET metabolic activity.…”

Section: Clinical Trials Of Stem Cell Transplantation For Stroke Patimentioning

confidence: 99%

Stem cell therapy in stroke

Locatelli

Bersano

Ballabio

et al. 2008

Cell. Mol. Life Sci.

110

View full text Add to dashboard Cite

Recent work has focused on cell transplantation as a therapeutic option following ischemic stroke, based on animal studies showing that cells transplanted to the brain not only survive, but also lead to functional improvement. Neural degeneration after ischemia is not selective but involves different neuronal populations, as well as glial and endothelial cell types. In models of stroke, the principal mechanism by which any improvement has been observed, has been attributed to the release of trophic factors, possibly promoting endogenous repair mechanisms, reducing cell death and stimulating neurogenesis and angiogenesis. Initial human studies indicate that stem cell therapy may be technically feasible in stroke patients, however, issues still need to be addressed for use in human subjects.

show abstract

Section: Clinical Trials Of Stem Cell Transplantation For Stroke Patimentioning

confidence: 99%

Stem cell therapy in stroke

Locatelli

Bersano

Ballabio

et al. 2008

Cell. Mol. Life Sci.

110

View full text Add to dashboard Cite

show abstract

“…Positron emission tomography scans were performed prior to implantation, and at 6 and 12 months after the procedure. Seven patients showed improvement in metabolism as measured by fluorodeoxyglucose uptake in the area of the infarct [40]. In some cases this improvement was not seen at 12 months, but in others it persisted.…”

Section: Neuronal Transplantationmentioning

confidence: 90%

Innovative strategies in the management of acute stroke

Wechsler

2002

Curr Cardiol Rep

View full text Add to dashboard Cite

Advances in acute stroke therapy are rapidly changing our approach to management of patients with ischemic stroke. Intravenous tissue-plasminogen activator (tPA) was the first treatment demonstrated in a randomized controlled trial to improve outcome if given within the first 3 hours of stroke onset. Subsequent trials failed to extend the time window for intravenous therapy beyond 3 hours. Intra-arterial thrombolysis provides an alternative approach, with several advantages over intravenous therapy. The major drawback is the additional time needed for the interventional procedure, and the equipment and personnel requirements. New strategies aimed at reducing the total time from stroke onset to recanalization of occluded arteries include a combined intravenous/ intra-arterial delivery of thrombolysis and mechanical devices. For the millions of stroke survivors, investigations are now underway into the possibility of improvement of function through neuronal transplantation.

show abstract

“…ASCs have been used for hematopoietic recovery after chemo-or radiotherapy in patients suffering from various types of cancer [101,[114][115][116], for immune system replacement in various autoimmune diseases [117][118][119][120], to treat various immunodeficiencies [121,122], anemia [123][124][125], corneal regeneration [126,127], wound healing [128], heart damage [129][130][131][132][133][134], stroke [135][136][137], spinal cord injury [138,139], liver cirrhosis [140] and chronic liver disease [141].…”

Section: Today's Therapy With Adult Stem Cellsmentioning

confidence: 99%

Promising New Sources for Pluripotent Stem Cells

Leeb

Jurga²,

McGuckin³

et al. 2009

Stem Cell Rev and Rep

View full text Add to dashboard Cite

Recent findings have placed stem cell research at the forefront of biomedical sciences. Basic research on embryonic stem cells (ESCs) has contributed to our knowledge about the developmental potential and plasticity of stem cells. Furthermore, it has raised hope to use these cells as potential source for regenerative medicine and tissue replacement after injury or disease. Unfortunately, ESCs can also form tumors and they are ethically controversial because they originate from human embryos. This review summarizes findings and therapeutic applications of ESCs and their alternatives: adult stem cells and iPS cells.

show abstract

Serial [18F]Fluorodeoxyglucose Positron Emission Tomography after Human Neuronal Implantation for Stroke

Cited by 40 publications

References 18 publications

Stem cell therapy in stroke

Stem cell therapy in stroke

Innovative strategies in the management of acute stroke

Promising New Sources for Pluripotent Stem Cells

Contact Info

Product

Resources

About